A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

By sjmartinez • February 15, 2023

Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). Arthritis Rheumatol. 2023 Feb 14. doi: 10.1002/art.42477. Epub ahead of print. PMID: 36787101.

Tags: Publications, Rheumatology

Subacute Combined Degeneration Due to Inhalant Use: Not a Laughing Matter

Lee SM, Goodman E, Szatkowski J. Subacute Combined Degeneration Due to Inhalant Use: Not a Laughing Matter. Cureus. 2025 Sep 16;17(9):e92459. doi: 10.7759/cureus.92459. PMID: 41111827;[...]

To Screen or Not to Screen Cutaneous Melanoma: A Case Report

Kim GS, Chen L, Chew J, Sandhu G, Wang AS. To Screen or Not to Screen Cutaneous Melanoma: A Case Report. Cureus. 2025 Sep 16;17(9):e92470.[...]

Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis

Singh S, Murad MH, Yuan Y, Ananthakrishnan AN, Click B, Syal G, Haydek JP, Agrawal M, Kappelman MD, Lewis JD, Scott FI. Comparative Efficacy of[...]